The effect of gonadotropin-releasing hormone analog treatment (leuprolide) on body fat distribution in idiopathic central precocious puberty

Tascilar M. E., BİLİR P., AKINCI A., Kose K., Akcora D., Inceoglu D., ...Daha Fazla

TURKISH JOURNAL OF PEDIATRICS, sa.1, ss.27-33, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2011
  • Dergi Adı: TURKISH JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.27-33
  • Anahtar Kelimeler: leuprolide, precocious puberty, obesity, body fat composition, body mass index, hyperinsulinism, BONE-MINERAL DENSITY, TERM-FOLLOW-UP, MASS INDEX, FINAL HEIGHT, INSULIN-RESISTANCE, OBESE CHILDREN, GIRLS, AGONIST, THERAPY, ADOLESCENTS
  • Ankara Üniversitesi Adresli: Evet

Özet

Gonadotropin-releasing hormone analog (GnRHa) therapy is used in idiopathic central precocious puberty (ICPP) worldwide. It has also been shown that during this therapy, body mass index (BMI) increases slightly as a side effect. We investigated the side effects of GnRHa treatment in ICPP on body composition and insulin resistance (IR). Twenty girls (7.55 +/- 1.02 y) with ICPP were treated with GnRHa (leuprolide) for an average of 20.83 +/- 4.8 months. Bioelectrical Impedance Analysis (BIA) was used to measure the body's fat balance. Nine patients out of 20 (45%) had significant gain weight. We showed a significant elevation in trunk fat mass compare to baseline values (p<0.01). These nine patients had high homeostasis model assessment (HOMA)-IR and low glucose/insulin (G/I) index. This study showed a slight increase in BMI, moderate increase in total body fat, and exaggerated elevation in trunk fat mass and IR in GnRHa-treated ICPP children.